FDA Plans Quick Review of Pfizer/BioNTech COVID-19 Booster For All Adults: NYT - Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE)

The FDA said it would review Pfizer Inc PFE / BioNTech SE's BNTX request to authorize COVID-19 booster doses of COVID-19 vaccine in all adults "as expeditiously as possible," with the New York Times reporting that the nod could come as soon as Thursday.
The agency said it does not plan to hold a meeting of the outside experts on Pfizer's request.
Related Link: Do You Need A COVID-19 Booster Dose? Pfizer-BioNTech Submit Initial Data To Support Idea.
The decision from the FDA will likely come before a U.S. Centers for Disease Control and Prevention (CDC) advisory panel meets on Friday to discuss expanding the eligibility for booster doses of Pfizer/BioNTech's vaccine.
Related: FDA Approves Vaccine Booster Dose Of mRNA COVID-19 Vaccines For Small, Vulnerable Group.
If both the FDA and the CDC sign off this week, any adult who received a second dose of the vaccine at least six months earlier would be officially eligible to get a booster as soon as this weekend.
Price Action: PFE shares are up 0.85% at $50.02, BNTX stock is up at 3.66% at $267.21 during the market session on the last check Wednesday.